Prucalopride in diabetic and connective tissue disease-related gastroparesis: Randomized placebo-controlled crossover pilot trial.

Christopher N AndrewsMatthew WooMichelle BuresiMichael CurleyMilli GuptaJan TackLynn WilsackYasmin Nasser

Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2020)

Prucalopride at 4 mg accelerates gastric emptying and bowel movement frequency but does not appear to ameliorate gastroparesis or meal-related symptoms in this study.

Keyphrases

placebo controlled
double blind
open label
phase iii
phase ii
clinical trial
type diabetes
study protocol
phase ii study
sleep quality
depressive symptoms